癌/睾丸抗原在多发性骨髓瘤免疫治疗中应用的研究进展  

Development of Cancer-testis Antigen in the Immunotherapy of Multiple Myeloma

作　　者：余培峰[1] 初明[1] 裴军[1] 徐碧荷[1] 陈咏冰[1] 连觅[1] 岳芳桦[1] 肖鹏[1] 赵昕淇[1] 丁然[2] 初正云[2] 王月丹[1] 

机构地区：[1]北京大学医学部基础医学院,北京100191 [2]辽宁中医药大学药学院,辽宁沈阳110032

出　　处：《现代生物医学进展》2012年第30期5946-5949,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金项目(81172884);国家基础科学人才培养基金(J1030831/J0108);北京大学创新人才培养计划;北京大学医学部新教师启动基金项目(BMU0239)

摘　　要：多发性骨髓瘤是一种常见的血液系统恶性肿瘤,经治疗后仍然有很多患者复发,严重威胁人类的健康。癌/睾丸抗原(C/T)抗原是只表达于睾丸和癌细胞的一类抗原,由于睾丸细胞缺少MHCⅠ类分子,不会受到特异性CTL的攻击,但C/T抗原本身具有一定的免疫原性,可以激活机体产生特异性的CTL应答,因此其被认为是目前肿瘤免疫治疗的理想靶分子之一。C/T抗原从1991年被首次报道以来就倍受关注,在此,本文主要综述了C/T抗原在骨髓瘤细胞中的表达及其在多发性骨髓瘤免疫治疗中的价值和前景。Multiple myeloma is a common hematologic malignancy which is a serious threaten to human health because many patients relapse after therapy. C/T antigen is a class of antigens that express only in testis and cancer ceils, as for testis ceils are lack of MHC class I molecules, they won＇t be attacked by special CTL. However, C/T antigen represents a kind of immunogenicity itself, it becomes one of the ideal target for immunotherapy of cancer, cfr antigen has drawn much attention since reported in 1991 for the first time, this summary mainly explains the expression of c/r antigen in multiple myeloma and the value or prospect of the application of C/T antigen in the immunotherapy of multiple myeloma.

关 键 词：C T抗原 多发性骨髓瘤 免疫治疗 

分 类 号：R733.3[医药卫生—肿瘤]